Citation Impact
Citing Papers
Pathological α-Synuclein Transmission Initiates Parkinson-like Neurodegeneration in Nontransgenic Mice
2012 StandoutScience
Deep Brain Stimulation for Treatment-Resistant Depression
2005 Standout
Bifluoride Ion Mediated SuFEx Trifluoromethylation of Sulfonyl Fluorides and Iminosulfur Oxydifluorides
2019 StandoutNobel
Acute and Longer-Term Outcomes in Depressed Outpatients Requiring One or Several Treatment Steps: A STAR*D Report
2006 Standout
Major depressive disorder
2016 Standout
Placebo Response in Studies of Major Depression
2002
Parkinson disease
2017 Standout
The Worldwide Prevalence of ADHD: A Systematic Review and Metaregression Analysis
2007 Standout
ALS Clinical Trials Review: 20 Years of Failure. Are We Any Closer to Registering a New Treatment?
2017
The Placebo Effect: Dissolving the Expectancy Versus Conditioning Debate.
2004 Standout
Monostars: An Aid to Choosing an Antiepileptic Drug as Monotherapy
1999
Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
2010 Standout
Monoamine Oxidase B Inhibitors for the Treatment of Parkinsonʼs Disease
2011
Hepatitis C Virus Infection
2001 Standout
Oxcarbazepine in painful diabetic neuropathy: results of a dose-ranging study
2006
Heterosexual Co-transmission of Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV)
1991
A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis
2010 Standout
Early Identification of Refractory Epilepsy
2000 Standout
Mechanisms Underlying Inflammation in Neurodegeneration
2010 Standout
Mitochondria in the aetiology and pathogenesis of Parkinson's disease
2008
PINK1 Is Selectively Stabilized on Impaired Mitochondria to Activate Parkin
2010 Standout
A Mitochondrial Protein Compendium Elucidates Complex I Disease Biology
2008 Standout
Ageing as a risk factor for neurodegenerative disease
2019 Standout
Oxcarbazepine in painful diabetic neuropathy: a randomized, placebo‐controlled study
2004
Trends in GPCR drug discovery: new agents, targets and indications
2017 Standout
Amyotrophic lateral sclerosis
2011 Standout
Pediatric Multiple Sclerosis
2011
Immunotherapy of myositis: issues, concerns and future prospects
2010
Prolonged Exposure to Sphingosine 1–Phosphate Receptor-1 Agonists Exacerbates Vascular Leak, Fibrosis, and Mortality after Lung Injury
2010
Checking consistency in mixed treatment comparison meta‐analysis
2010 Standout
Global epidemiology of hepatitis C virus infection
2005 Standout
Pharmacologic management of neuropathic pain: Evidence-based recommendations
2007 Standout
Effects of Antiepileptic Drugs on Sleep Structure
2003
The Endocannabinoid System as an Emerging Target of Pharmacotherapy
2006 Standout
Clinical effectiveness, tolerability and cost-effectiveness of newer drugs for epilepsy in adults: a systematic review and economic evaluation
2005
Pharmacological Approaches to the Management of Secondary Progressive Multiple Sclerosis
2017
Parkinson's disease
2015 Standout
Modulation of GABAA receptor desensitization uncouples sleep onset and maintenance in Drosophila
2008 StandoutNobel
Drug repurposing: progress, challenges and recommendations
2018 Standout
The New Antiepileptic Drugs
2004
Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial
2007
FTY720 (fingolimod) in Multiple Sclerosis: therapeutic effects in the immune and the central nervous system
2009
Mechanisms of mitophagy
2010 Standout
Hepatitis C virus-specific T lymphocyte responses
1995 StandoutNobel
The immunology of stroke: from mechanisms to translation
2011 Standout
Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues
2008 Standout
Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis
2009 Standout
Attention-deficit/hyperactivity disorder with obstructive sleep apnea: A treatment outcome study
2006
Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria
2011 Standout
Neurotoxic in vivo models of Parkinson’s disease
2010
Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis
2010
Nanomedicines accessible in the market for clinical interventions
2020
Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial
2007 Standout
Non-motor features of Parkinson disease
2017 Standout
Molecular and clinical prodrome of Parkinson disease: implications for treatment
2010
Attention-deficit hyperactivity disorder
2005
Polymeric micelles in drug delivery: An insight of the techniques for their characterization and assessment in biorelevant conditions
2021 Standout
The acute respiratory distress syndrome
2012 Standout
Pathogenesis-Targeted, Disease-Modifying Therapies in Parkinson Disease
2013
DEFINITION AND EPIDEMIOLOGY OF TREATMENT-RESISTANT DEPRESSION
1996
The rise and rise of drug delivery
2005
Enhanced Sensitivity of a Second Generation ELISA for Antibody to Hepatitis C Virus
1992 StandoutNobel
Efficacy and Safety of Dexmethylphenidate Extended-Release Capsules in Children With Attention-Deficit/Hyperactivity Disorder
2006
Inflammatory Muscle Diseases
2015 Standout
Fluorine and Fluorinated Motifs in the Design and Application of Bioisosteres for Drug Design
2018 Standout
Detection of parvovirus B19 in donated blood: a model system for screening by polymerase chain reaction
1993
Natural Products as Sources of New Drugs over the Nearly Four Decades from 01/1981 to 09/2019
2020 Standout
Human Parvovirus B19
2002 Standout
Multiple Sclerosis
2018 Standout
Degradable Controlled-Release Polymers and Polymeric Nanoparticles: Mechanisms of Controlling Drug Release
2016 Standout
Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II–III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas
2016 Standout
A Randomized, Double-Blind, Placebo-Controlled, Laboratory Classroom Assessment of Methylphenidate Transdermal System in Children With ADHD
2006
Practice Parameter for the Assessment and Treatment of Children and Adolescents With Attention-Deficit/Hyperactivity Disorder
2007 Standout
Executive Functions
2012 Standout
The Latest Innovations in the Drug Pipeline for Multiple Sclerosis.
2015
A systematic review and economic model of the effectiveness and cost-effectiveness of methylphenidate, dexamfetamine and atomoxetine for the treatment of attention deficit hyperactivity disorder in children and adolescents
2006
A multicenter study of viral hepatitis in a United States hemophilic population
1993
Fingolimod (FTY720): A Recently Approved Multiple Sclerosis Drug Based on a Fungal Secondary Metabolite
2011
Molecular and clinical pathways to neuroprotection of dopaminergic drugs in Parkinson disease
2009
Increasing hepatitis C virus RNA levels in hemophiliacs: relationship to human immunodeficiency virus infection and liver disease. Multicenter Hemophilia Cohort Study
1994
Modulators of Sphingosine-1-phosphate Pathway Biology: Recent Advances of Sphingosine-1-phosphate Receptor 1 (S1P1) Agonists and Future Perspectives
2017
PINK1 stabilized by mitochondrial depolarization recruits Parkin to damaged mitochondria and activates latent Parkin for mitophagy
2010 Standout
Natural Products As Sources of New Drugs over the 30 Years from 1981 to 2010
2012 Standout
Experimental Analysis of Neighborhood Effects
2007 Standout
Systematic reviews: CRD's guidance for undertaking reviews in health care
2010 Standout
Works of H. Pöhlmann being referenced
TCH346 as a neuroprotective drug in Parkinson's disease: a double-blind, randomised, controlled trial
2006
Prevalence of antibodies to hepatitis C virus (HCV) in haemophiliacs
1989
A Canadian multicentre placebo-controlled study of a fixed dose of brofaromine, a reversible selective MAO-A inhibitor, in the treatment of major depression
1994
Efficacy and Safety of Ritalin?? LA???, a New, Once Daily, Extended-Release Dosage Form of Methylphenidate, in Children with Attention Deficit Hyperactivity Disorder
2003
A double-blind controlled clinical trial of oxcarbazepine versus phenytoin in adults with previously untreated epilepsy
1997
Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study
2013
A double-blind controlled clinical trial: oxcarbazepine versus sodium valproate in adults with newly diagnosed epilepsy
1997
Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3-year results
2009
Oral fingolimod (FTY720) in multiple sclerosis
2009
Siponimod (BAF312) for the treatment of secondary progressive multiple sclerosis: Design of the phase 3 EXPAND trial
2014
A double-blind controlled clinical trial of oxcarbazepine versus phenytoin in children and adolescents with epilepsy
1997
Phase II/III randomized trial of TCH346 in patients with ALS
2007